EQS-Adhoc: Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares

NOT TO BE TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO OR WITHIN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTIONS IN WHICH SUCH TRANSMISSION OR DISTRIBUTION WOULD BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE REFER TO THE IMPORTANT NOTES AT THE END OF THIS AD-HOC NOTIFICATION.

Publication of inside information pursuant to Article 17 (1) of Regulation (EU) 596/2014 on market abuse (Market Abuse Regulation – MAR)

Dermapharm Holding SE resolves public share buyback offer for up to 4,300,000 shares

Grünwald, Germany, 10 March 2026 – The Management Board of Dermapharm Holding SE (the "Company") (ISIN DE000A2GS5D8 / WKN A2GS5D) resolved today, with the approval of the Supervisory Board of the Company and on the basis of the authorization granted by the Annual General Meeting of the Company on 14 June 2023, to make a public share buyback offer to the shareholders of Dermapharm Holding SE for a total of up to 4,300,000 shares (representing approximately 7.99% of the share capital of the Company) at an offer price of EUR 42.00 per share. The repurchased shares are intended to be cancelled.

The acceptance period commences on 11 March 2026 at 00:00 hours (CET) and ends, subject to an extension by the Company, on 24 March 2026 at 24:00 hours (CET). If more than 4,300,000 shares are tendered for repurchase into the offer, acceptances will be taken into account on a pro-rata basis in the ratio of 4,300,000 shares to the total number of shares tendered for repurchase by the shareholders. Further details of the public share buyback offer are included in the offer document, which will be published on the website of Dermapharm Holding SE (https://ir.dermapharm.de) under the heading “Investor Relations – Share – Share Buyback – 2026” and, thereafter, in the Federal Gazette (Bundesanzeiger) at www.bundesanzeiger.de.

Contact

Investor Relations & Corporate Communications
Britta Hamberger
Tel.: +49 (0)89 – 64186-233
E-mail: ir@dermapharm.com

Disclaimer

This notification may not be published, distributed or transmitted in the United States of America, Canada, Australia or Japan. This notification is not directed at, or intended to be transmitted to or used by, any person who is a national or resident of, or located in, any state, country or other jurisdiction where the transmission, publication, use or making available of this notification would violate applicable law or would require a registration or license within such jurisdiction.

Neither this notification nor its content may be published, sent, distributed or disseminated in the United States of America by use of any postal service or by any other means or instrument of interstate commerce or of foreign trade or of the facilities of any national stock exchange of the United States of America. This includes, but is not limited to, fax transmission, electronic mail, telex, telephone and the Internet. Copies of this notification and other related documents may not be sent or transmitted to or within the United States of America either.

This notification does not constitute an offer for the purchase of securities, or a solicitation to make an offer for the purchase of securities, of the Company in the United States of America, Germany or any other jurisdiction.

This notification contains forward-looking statements. These statements are based on the current views, expectations and assumptions of Dermapharm Holding SE’s management and entail known and unknown risks and uncertainties that may cause the actual results, performance or events to differ materially from those expressed or implied by the forward-looking statements. The actual results, performance or events may differ materially from those described therein due to, among other things, changes in the general economic environment or competitive situation, risks associated with capital markets, foreign exchange rate fluctuations and competition from other companies, changes in a foreign or domestic legal system, particularly with respect to the tax environment, or other factors. Dermapharm Holding SE assumes no obligation to update forward-looking statements.

2288356  10-March-2026 CET/CEST